Next Article in Journal
Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice
Next Article in Special Issue
“Things Have Changed”—Laparoscopic Cytoreduction for Advanced and Recurrent Ovarian Cancer: The Experience of a Referral Center on 108 Patients
Previous Article in Journal
Functional Outcome and Overall Survival in Patients with Primary or Secondary CNS Lymphoma after Surgical Resection vs. Biopsy
Previous Article in Special Issue
Optimal Management for Stage IVB Endometrial Cancer: A Systematic Review
 
 
Article
Peer-Review Record

A Novel Predictive Multi-Marker Test for the Pre-Surgical Identification of Ovarian Cancer

Cancers 2023, 15(21), 5267; https://doi.org/10.3390/cancers15215267
by Andrew N. Stephens 1,2,3,*, Simon J. Hobbs 3, Sung-Woon Kang 1,2, Maree Bilandzic 1,2, Adam Rainczuk 1,2,4, Martin K. Oehler 5,6, Tom W. Jobling 7, Magdalena Plebanski 8 and Richard Allman 3
Reviewer 1:
Reviewer 2:
Cancers 2023, 15(21), 5267; https://doi.org/10.3390/cancers15215267
Submission received: 15 October 2023 / Revised: 27 October 2023 / Accepted: 27 October 2023 / Published: 2 November 2023
(This article belongs to the Special Issue Gynecologic Cancer: From Diagnosis to Treatment)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

The authors propose a novel model that tests for evaluation and detection of early-stage ovarian cancers. The multi-marker model developed using patient samples has been well described and explained throughout the manuscript. The multi-marker test proposed achieves a fairly high percentage of sensitivity and specificity in the given cohort.

 

However, it would be better if the authors improve the quality of the images of the equations (Line 200, 213, 217). Also, the authors should improve the quality of figure 2. It appears to be pixelated, as well. 

Author Response

Reviewer 1:
 …it would be better if the authors improve the quality of the images of the equations (Line 200, 213, 217). Also, the authors should improve the quality of figure 2. It appears to be pixelated, as well.

Response: New higher resolution versions of the equations have been generated and inserted into the text. High resolution copies of each figure have also been uploaded to the publishers website for use.

Reviewer 2 Report

Comments and Suggestions for Authors

The manuscript is very well written and the authors claim that their multi-marker panel provides improved differentiation of benign from malignant disease and the associated scoring algorithm provide a useful measurement to assist in presurgical diagnosis and triage of patients with a suspected ovarian cancer. 

The introduction and method section are well written. 

Please provide a decent size of Figure 1A as it is hard to read the text in the figure. Figure 1B can be reduced to compensate for the enlargement of figure 1A.  

In order to clearly discrimination between benign and malignant samples Figure 2A needs to be presented in a better to understand how each sample was compared using the comparisons of the multi-marker panel score made against standard cut-off values for multi-marker panel.

The manuscript is well written but lacks the proper representative figures. 

Author Response

Reviewer 2:
1: Please provide a decent size of Figure 1A as it is hard to read the text in the figure. Figure 1B can be reduced to compensate for the enlargement of figure 1A. 
Response: The layout of Figure 1 has been altered to increase the size of graphs in Fig 1A, and decrease the size of Fig 1B as suggested.

2: Figure 2A needs to be presented in a better to understand how each sample was compared using the comparisons of the multi-marker panel score made against standard cut-off values for multimarker panel.
Response: The ROC curve is a standard method to define and view binary classifier performance, using the specific cut-off values provided. To assist the reader in interpreting the data, we have added the following text to the legend of Figure 2A; Cutoff values for each marker were; multi-marker panel 3.68; CA125 >35U/ml, RMI >200 and ROMA pre-menopausal >13.1% or post-menopausal >27.7%.

Back to TopTop